Tempest Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Francisco CA United States (2011)

Organization Overview

First Clinical Trial
2019
NCT03829436
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tempest Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Tempest Therapeutics (0) Acquired (1)

azp-531 (2 trials)

Drugs in Phase 2 Trials (3)

Key: Tempest Therapeutics (0) Acquired (3)

atr-101 (3 trials)

azd-2624 (1 trial)

nevanimibe hydrochloride (1 trial)

Drugs in Phase 1 Trials (6)

cetuximab (erbitux) (1 trial)

docetaxel (taxotere) (1 trial)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (1 trial)

tpst-1120 (1 trial)

tpst-1495 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Adenocarcinoma of Lung (Phase 1)

Carcinoma (Phase 1)

Cholangiocarcinoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 9
  • # of Trial APIs: 10